Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharm Pract (Granada) [Internet]. 2006 Dec. 12 [cited 2026 Apr. 16];4(4):168-7. Available from: https://pharmacypractice.org/index.php/pp/article/view/272